PRPO
Precipio, Inc. NASDAQ Listed Jun 30, 2017$28.85
-1.50%
vs $29.29
Mkt Cap $51.5M
52w Low $14.28
75.3% of range
52w High $33.63
50d MA $24.46
200d MA $24.90
P/E (TTM)
—
EV/EBITDA
46.9x
P/B
3.2x
Debt/Equity
0.2x
ROE
-2.5%
P/FCF
129.0x
RSI (14)
77.70
ATR (14)
$2.24
Beta
1.20
50d MA
$24.46
200d MA
$24.90
Avg Volume
127.1K
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
4 Science Park · New Haven, CT 06511 · US
Data updated apr 26, 2026 8:49pm
· Source: financialmodelingprep.com